Item 2.02 Results of Operations and Financial Condition.

On January 10, 2022, Ultragenyx Pharmaceutical Inc. (the "Company") issued a press release (the "Press Release") announcing preliminary unaudited fiscal year 2021 revenue for Crysvita® in the Ultragenyx territories and Dojolvi® global revenue, cash and investments at 2021 fiscal year end and 2022 revenue guidance for Crysvita® in the Ultragenyx territories and Dojolvi®. Ultragenyx territories for Crysvita® include the collaboration revenue from the North American profit share territory of the United States and Canada and other regions where revenue from product sales are recognized by the Company, including Latin America and Turkey, pursuant to the Company's collaboration and license agreement with Kyowa Kirin Co., Ltd. The Company expects to report its full year results for the 2021 fiscal year in February 2022. A copy of the Press Release is furnished herewith as Exhibit 99.1.

The information set forth under Item 2.02 and in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

Item 7.01 Regulation FD Disclosure.

On January 10, 2022, the Company posted a presentation (the "Presentation") to its website at www.ultragenyx.com in the "Events and Presentations" subsection of the "Investors & Media" tab. The Company is scheduled to present the Presentation at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022.

The information set forth under Item 7.01 and in the Presentation shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in any such filing.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits



Exhibit No. Description
99.1          Press Release, dated January 10, 2022.
104         The cover page from the Company's Current Report on Form 8-K dated
            January 10, 2022 formatted in Inline XBRL.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses